Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man

Adriaan G. Holleboom(Amsterdam University Medical Centers), Jan Albert Kuivenhoven(University Medical Center Groningen), Johannes M. F. G. Aerts(Leiden University Medical Center), Thomas M. Beres(National Institutes of Health), Jonathan G. Seidman(Harvard University), Mohammad Mahdi Motazacker(Max Planck Institute for Molecular Genetics), Ron A. Wevers(Radboud University Nijmegen), Ruei-Shiuan Lin(National Institutes of Health), Lawrence A. Tabak(National Institutes of Health), Aeilko H. Zwinderman(Amsterdam Neuroscience), Helén Karlsson(Linköping University), Stefan Ljunggren(Linköping University), Mats Lindahl(Linköping University), Geesje M. Dallinga‐Thie(Amsterdam UMC Location University of Amsterdam), Éva Morava(Institut thématique Génétique, génomique et bioinformatique), Daniel S. Herman(Harvard University), John J.P. Kastelein(QRx Pharma (United States)), Jeroen A. Sierts(Amsterdam UMC Location University of Amsterdam), Timothy A. Fritz(United States Food and Drug Administration), Erik S.G. Stroes(Amsterdam University Medical Centers), Johannes H.M. Levels(Amsterdam UMC Location University of Amsterdam), G. Kees Hovingh(Novo Nordisk (Denmark)), Dirk J. Lefeber(Radboud University Nijmegen), Christine E. Seidman(Harvard University)
Cell Metabolism
December 1, 2011
Cited by 100


Related Papers